IV機器市場規模、シェア、動向、2031年までの世界予測

世界のIV機器市場は、予測期間中に6.1%のCAGRで成長し、2026年の178.2億米ドルから2031年には239.2億米ドルに達すると予測されています。

世界中で慢性疾患の罹患率と入院患者数が増加していることを背景に、IV機器の需要は着実に増加しています。薬剤投与、水分補給、栄養補給のためのIV療法の導入拡大と、在宅ケアや外来ケアへの移行が、製品利用率を押し上げています。病院やクリニックは、正確な薬剤投与と患者の安全確保のため、高品質で安全かつ使いやすいIV機器を優先的に採用しています。ニードルフリーコネクタ、スマート輸液ポンプ、互換性のあるマルチパラメータIVシステムなどの技術革新も、市場での普及をさらに促進しています。さらに、新興国における医療インフラの拡充と、近代的な医療慣行を促進する政府の積極的な取り組みにより、今後数年間は市場の力強い成長が持続すると予想されます。

調査範囲

本レポートは、IV機器市場をタイプ、用途、エンドユーザー、地域別に分析しています。また、市場の成長に影響を与える要因、市場における様々な機会と課題を分析し、市場リーダーの競争環境の詳細も提供しています。さらに、マイクロマーケットを個々の成長傾向に基づいて分析し、5つの主要地域（および各地域に属する国）における市場セグメントの収益予測も行っています。

レポートを購入する理由

本レポートは、既存企業だけでなく新規参入企業や小規模企業も市場の動向を把握し、より大きな市場シェアを獲得することを可能にします。本レポートを購入した企業は、以下の戦略のいずれか、または組み合わせて活用することで、市場プレゼンスを強化できます。

本レポートは、以下の点について洞察を提供します。

• IV機器市場の成長に影響を与える主要な推進要因（世界的な疾病負担の増加とそれに伴う高齢者人口の急増、そして在宅および外来輸液への移行）、制約要因（製品リコールや不具合）、機会（新興市場における未開拓の成長ポテンシャル）、課題（ベンダーとの連携）の分析。
• 市場浸透：IV機器市場における主要プレーヤーが提供する製品ポートフォリオに関する包括的な情報。
• 製品開発／イノベーション：IV機器市場における今後のトレンド、研究開発活動、製品開発に関する詳細な洞察。
• 市場発展：収益性の高い新興地域に関する包括的な情報。
• 市場多様化：IV機器市場における新製品、成長地域、最近の動向に関する包括的な情報。
• 競合評価：市場セグメント、成長戦略、収益分析、主要プレーヤーの製品に関する詳細な評価。

Report Description

The global IV equipment market is projected to reach USD 23.92 billion by 2031 from USD 17.82 billion in 2026, growing at a CAGR of 6.1% during the forecast period.

The demand for IV equipment is growing steadily, driven by the rising prevalence of chronic diseases and increasing hospitalizations worldwide. The growing adoption of IV therapy for medication administration, hydration, and nutrition, along with the shift toward home-based and outpatient care, is boosting product utilization. Hospitals and clinics are prioritizing high-quality, safe, and user-friendly IV devices to ensure accurate drug delivery and patient safety. Technological innovations, such as needle-free connectors, smart infusion pumps, and compatible multi-parameter IV systems, are further enhancing market adoption. Moreover, expanding healthcare infrastructure in emerging economies and favorable government initiatives promoting modern healthcare practices are expected to sustain strong market growth in the coming years.

“By type, the needle-free connectors & extension sets segment is projected to grow significantly during the forecast period.”

Based on type, needle-free connectors & extension sets are the fastest-growing segment in the IV equipment market, driven by their enhanced safety, ease of use, and ability to significantly reduce the risk of infections and needlestick injuries. These connectors streamline medication administration, reduce contamination, and improve workflow efficiency in hospitals, clinics, and home care settings. Their growing adoption is also supported by stringent infection control regulations and increasing awareness among healthcare providers about patient safety, making them a highly preferred choice in modern healthcare facilities.

“By application, the medication administration segment held the largest market share in 2025.”

By application, medication administration holds the largest market share in the IV equipment market, as IV therapy allows drugs to be delivered directly into the bloodstream, ensuring rapid onset of action, precise dosing, and optimal therapeutic effectiveness. This application is particularly critical in intensive care units, chemotherapy treatments, pain management, and severe infection management, where timely and accurate drug delivery can significantly improve patient outcomes. The growing prevalence of chronic and acute diseases, along with increasing hospital admissions, continues to drive the demand for IV-based medication administration.

“By region, North America accounted for the largest market share in 2025.”

The IV equipment market is segmented into North America, Europe, Latin America, the Asia Pacific, and the Middle East & Africa. North America leads the global IV equipment market. This dominance is attributed to the high prevalence of chronic diseases, well-established healthcare infrastructure, and rapid adoption of advanced medical technologies. Additionally, the strong presence of key market players, increased healthcare spending, and growing demand for advanced infusion systems in hospitals and home healthcare settings further contribute to the region’s leading market position.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1 (35%), Tier 2 (40%), and Tier 3 (25%)
• By Designation: Directors (25%), Managers (50%), and Others (25%)
• By Region: North America (35%), Europe (30%), the Asia Pacific (15%), and the Rest of the World (20%)

The prominent players in the IV equipment market are Becton, Dickinson and Company (US), B. Braun SE (Germany), Fresenius SE & Co. KGaA (Germany), ICU Medical, Inc. (US), Terumo Corporation (Japan), Moog Inc. (US), Teleflex Incorporated (US), Cardinal Health (US), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Baxter (US), Avanos Medical, Inc. (US), Nipro (Japan), JMS Co., Ltd. (Japan), Vygon (France), and Micrel Medical Devices SA (Greece), among others.

Research Coverage

This report analyzes the IV equipment market by type, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets by their individual growth trends and forecasts market segment revenues across five main regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the following strategies to strengthen their market presence.

This report provides insights into the following pointers:

• Analysis of key drivers (rising disease burden and the subsequent surge in the geriatric population globally as well as the shift toward home and ambulatory infusion), restraints (product recalls and failures), opportunities (untapped growth potential in emerging markets), and challenges (vendor collaborations) influencing the growth of the IV equipment market.
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the IV equipment market.
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product developments in the IV equipment market.
• Market Development: Comprehensive information on lucrative emerging regions.
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the IV equipment market.
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

Table of Contents

1 INTRODUCTION 34
1.1 STUDY OBJECTIVES 34
1.2 MARKET DEFINITION 34
1.3 STUDY SCOPE 35
1.3.1 SEGMENTS CONSIDERED & GEOGRAPHICAL SCOPE 35
1.3.2 INCLUSIONS & EXCLUSIONS 36
1.3.3 YEARS CONSIDERED 37
1.4 CURRENCY CONSIDERED 37
1.5 STAKEHOLDERS 38
1.6 SUMMARY OF CHANGES 38
2 EXECUTIVE SUMMARY 40
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 40
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 41
2.3 DISRUPTIVE TRENDS IN IV EQUIPMENT MARKET 42
2.4 HIGH-GROWTH SEGMENTS 43
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 44
3 PREMIUM INSIGHTS 45
3.1 IV EQUIPMENT MARKET OVERVIEW 45
3.2 ASIA PACIFIC: IV EQUIPMENT MARKET, BY COUNTRY AND END USER 46
3.3 GEOGRAPHIC SNAPSHOT OF IV EQUIPMENT MARKET 47
4 MARKET OVERVIEW 48
4.1 INTRODUCTION 48
4.2 MARKET DYNAMICS 48
4.2.1 DRIVERS 49
4.2.1.1 Rising disease burden and subsequent surge in geriatric population globally 49
4.2.1.2 Shift toward home and ambulatory infusion 49
4.2.1.3 Smart pumps, improved safety features, and precision infusion systems 50
4.2.2 RESTRAINTS 50
4.2.2.1 Product recalls and failures 50
4.2.2.2 Infection and complication risk associated with IV therapy 51
4.2.3 OPPORTUNITIES 51
4.2.3.1 Untapped growth potential in emerging markets 51
4.2.3.2 Technological advancements and vendor collaborations 52

4.2.4 CHALLENGES 52
4.2.4.1 Device reliability, maintenance requirements, and user-related errors 52
4.3 UNMET NEEDS & WHITE SPACES 53
4.3.1 UNMET NEEDS IN IV EQUIPMENT MARKET 53
4.3.1.1 Interoperable & smart IV systems 53
4.3.1.2 Affordable, reliable equipment for emerging markets 53
4.3.1.3 Better infection-prevention designs 53
4.3.1.4 Home care & ambulatory-friendly IV devices 53
4.3.1.5 Streamlined regulatory pathways 53
4.3.1.6 Wider access & supply consistency 53
4.3.2 WHITE SPACE OPPORTUNITIES 53
4.3.2.1 Low-cost smart infusion pumps for emerging markets 53
4.3.2.2 Integrated IV ecosystem 54
4.3.2.3 Home infusion & ambulatory-first devices 54
4.3.2.4 Infection-prevention IV consumables 54
4.3.2.5 Disposable/Single-use smart components 54
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 55
4.4.1 INTERCONNECTED MARKETS 55
4.4.2 CROSS-SECTOR OPPORTUNITIES 55
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 56
4.5.1 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 56
5 INDUSTRY TRENDS 57
5.1 PORTER’S FIVE FORCES ANALYSIS 57
5.1.1 THREAT OF NEW ENTRANTS 58
5.1.2 THREAT OF SUBSTITUTES 58
5.1.3 BARGAINING POWER OF SUPPLIERS 59
5.1.4 BARGAINING POWER OF BUYERS 59
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 59
5.2 MACROECONOMIC INDICATORS 59
5.2.1 INTRODUCTION 59
5.2.2 GDP TRENDS & FORECAST 59
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 61
5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY 61
5.3 SUPPLY CHAIN ANALYSIS 61
5.4 VALUE CHAIN ANALYSIS 63
5.5 MARKET ECOSYSTEM 64
5.5.1 ROLE IN ECOSYSTEM 65
5.6 PRICING ANALYSIS 65
5.6.1 AVERAGE SELLING PRICE TREND OF IV EQUIPMENT, BY KEY PLAYER,
2023–2025 (USD) 66
5.6.2 AVERAGE SELLING PRICE TREND OF INFUSION PUMPS, BY REGION,
2023–2025 (USD) 67
5.7 TRADE ANALYSIS 68
5.7.1 IMPORT DATA (HS CODE 901890) 68
5.7.2 EXPORT DATA (HS CODE 901890) 69
5.8 REIMBURSEMENT SCENARIO 69
5.9 KEY CONFERENCES & EVENTS, 2026–2027 70
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 71
5.11 INVESTMENT & FUNDING SCENARIO 72
5.12 CASE STUDY ANALYSIS 73
5.13 IMPACT OF 2025 US TARIFFS ON IV EQUIPMENT MARKET 75
5.13.1 INTRODUCTION 75
5.13.2 KEY TARIFF RATES 76
5.13.3 PRICE IMPACT ANALYSIS 76
5.13.4 IMPACT ON COUNTRY/REGION 77
5.13.5 IMPACT ON END-USE SEGMENTS 79
5.13.5.1 Hospitals 79
5.13.5.2 Outpatient infusion & specialty clinics 79
5.13.5.3 Ambulatory surgical centers (ASCs) 79
5.13.5.4 Home care settings 79
5.13.5.5 Other end users (long-term care facilities, emergency services, and specialty clinics) 79
6 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY,
PATENTS, AND DIGITAL & AI ADOPTION 80
6.1 TECHNOLOGY ANALYSIS 80
6.1.1 KEY EMERGING TECHNOLOGIES 80
6.1.1.1 Smart infusion pumps 80
6.1.1.2 Closed-loop infusion control systems 80
6.1.2 COMPLEMENTARY TECHNOLOGIES 80
6.1.2.1 Dose-error reduction systems 80
6.1.2.2 Telemedicine & remote infusion monitoring 81
6.1.3 ADJACENT TECHNOLOGIES 81
6.1.3.1 Embedded software 81
6.2 TECHNOLOGY/PRODUCT ROADMAP 82
6.2.1 NEAR TERM (2025–2027) 82
6.2.2 MID TERM (2028–2030) 82
6.2.3 LONG TERM (2030+) 82
6.3 PATENT ANALYSIS 83
6.3.1 JURISDICTION & TOP APPLICANT ANALYSIS 83
6.4 FUTURE APPLICATIONS 85
6.4.1 REMOTE & HOME-BASED INFUSION THERAPY 85
6.4.2 CLOSED-LOOP IV THERAPY & AUTOMATED DOSING 85
6.4.3 AI-DRIVEN INFUSION SAFETY & PREDICTIVE QUALITY MANAGEMENT 85
6.5 IMPACT OF AI/GEN AI ON IV EQUIPMENT MARKET 86
6.5.1 INTRODUCTION 86
6.5.2 MARKET POTENTIAL OF AI IN IV EQUIPMENT 86
6.5.3 AI USE CASES 86
6.5.4 KEY COMPANIES IMPLEMENTING AI 88
7 SUSTAINABILITY & REGULATORY LANDSCAPE 89
7.1 REGULATORY LANDSCAPE 89
7.1.1 REGULATORY FRAMEWORK 89
7.1.1.1 North America 89
7.1.1.2 Europe 89
7.1.1.3 Asia Pacific 89
7.1.1.4 Latin America 90
7.1.1.5 Middle East & Africa 90
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
7.1.3 INDUSTRY STANDARDS 93
7.2 SUSTAINABILITY INITIATIVES 94
7.2.1 RECYCLED AND ECO-FRIENDLY MATERIALS FOR IV EQUIPMENT 94
7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 94
7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 95
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 96
8.1 KEY STAKEHOLDERS & BUYING CRITERIA 96
8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS 96
8.1.2 BUYING CRITERIA 97
8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 98
8.2.1 DECISION-MAKING PROCESS 98
8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES 99
8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 99
8.2.4 MARKET PROFITABILITY 100
9 IV EQUIPMENT MARKET, BY TYPE 101
9.1 INTRODUCTION 102
9.2 IV CATHETERS 102
9.2.1 GROWING HOSPITAL ADMISSIONS AND VASCULAR ACCESS DEMAND TO DRIVE USE OF IV CATHETERS 102
9.3 INFUSION PUMPS 104
9.3.1 SHIFT TOWARD PRECISION MEDICINE AND DIGITAL SAFETY TO ACCELERATE SMART PUMP ADOPTION 104
9.4 IV ADMINISTRATION SETS & TUBING 107
9.4.1 HIGH-VOLUME THERAPY DEMAND AND SUPPLY CHAIN RESILIENCE TO DRIVE IV SET CONSUMPTION 107

9.5 SECUREMENT & STABILIZATION DEVICES 108
9.5.1 GROWING CLINICAL EMPHASIS ON LINE STABILITY AND INFECTION PREVENTION TO ELEVATE SECUREMENT DEMAND 108
9.6 NEEDLE-FREE CONNECTORS & EXTENSION SETS 110
9.6.1 NEEDLESTICK PREVENTION AND INFECTION CONTROL POLICIES TO EXPAND CONNECTOR ADOPTION 110
9.7 IV DRIP CHAMBERS 112
9.7.1 ESSENTIAL FLOW-CONTROL COMPONENTS TO SUPPORT HIGH-VOLUME GRAVITY INFUSIONS 112
9.8 OTHER IV EQUIPMENT 114
10 IV EQUIPMENT MARKET, BY APPLICATION 117
10.1 INTRODUCTION 118
10.2 MEDICATION ADMINISTRATION 118
10.2.1 ONCOLOGY (IV CHEMOTHERAPY) 120
10.2.1.1 Rising cancer burden to drive market growth 120
10.2.2 ANTIBIOTIC/ANTIMICROBIAL IV THERAPY 122
10.2.2.1 Prolonged antibiotic therapy to boost market growth 122
10.2.3 CRITICAL CARE & VASOACTIVE DRUG INFUSION 123
10.2.3.1 Demand for advanced IV pumps and compatible disposables to aid market growth 123
10.2.4 ANALGESIA/PAIN MANAGEMENT 125
10.2.4.1 Surge in chronic pain conditions to propel market growth 125
10.2.5 SEDATION & ANESTHESIA INFUSION 127
10.2.5.1 High procedural sedation demand to propel market growth 127
10.2.6 IMMUNOTHERAPY 128
10.2.6.1 Increasing use in immune-mediated conditions to support market growth 128
10.3 PARENTERAL NUTRITION (PN) 130
10.3.1 GASTROINTESTINAL DISORDERS 132
10.3.1.1 Rising GI disorders to support market growth 132
10.3.2 CRITICAL CARE NUTRITION 133
10.3.2.1 Increasing demand in ICU units to support market growth 133
10.3.3 NEONATAL & PEDIATRIC PARENTERAL NUTRITION 135
10.3.3.1 Increasing demand for neonatal lipid formulations to propel market growth 135
10.3.4 OTHER PARENTERAL NUTRITION APPLICATIONS 136
10.4 FLUID & ELECTROLYTE REPLACEMENT 138
10.4.1 GROWING DEMAND FOR FLUID AND REPLACEMENT THERAPY TO DRIVE MARKET GROWTH 138
10.5 BLOOD & BLOOD PRODUCTS TRANSFUSION 139
10.5.1 RED BLOOD CELL TRANSFUSION 141
10.5.1.1 Growing use in symptomatic anemia, acute blood loss, and perioperative blood replacement to support market growth 141
10.5.2 PLATELET TRANSFUSION 143
10.5.2.1 Growing use of standard blood administration sets to fuel growth 143
10.5.3 PLASMA TRANSFUSION 144
10.5.3.1 Wide usage in critical therapy for coagulation disorders to expand market 144
10.5.4 OTHER BLOOD & BLOOD PRODUCTS TRANSFUSION APPLICATIONS 146
10.6 DIAGNOSTIC TESTING 147
10.6.1 INCREASING DEMAND FOR DIAGNOSTIC IMAGING PROCEDURES TO AID MARKET GROWTH 147
10.7 OTHER APPLICATIONS 149
11 IV EQUIPMENT MARKET, BY END USER 151
11.1 INTRODUCTION 152
11.2 HOSPITALS 152
11.2.1 HIGH DEMAND AND COMPLEX INFUSION WORKFLOWS TO SUSTAIN HOSPITAL DOMINANCE IN IV EQUIPMENT USE 152
11.3 AMBULATORY SURGICAL CENTERS 154
11.3.1 GROWING NUMBER OF SURGICAL PROCEDURES IN ASCS TO PROPEL MARKET GROWTH 154
11.4 OUTPATIENT INFUSION & SPECIALTY CLINICS 155
11.4.1 HIGH DEMAND FOR IV CONSUMABLES AND INFUSION PUMPS TO DRIVE MARKET GROWTH 155
11.5 HOME CARE SETTINGS 157
11.5.1 EXPANSION OF HOME INFUSION THERAPY TO CREATE NEW DEMAND FOR PORTABLE IV DEVICES AND CONSUMABLES 157
11.6 OTHER END USERS 159
12 IV EQUIPMENT MARKET, BY REGION 161
12.1 INTRODUCTION 162
12.2 NORTH AMERICA 163
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 163
12.2.2 US 168
12.2.2.1 US to dominate North American IV equipment market 168
12.2.3 CANADA 171
12.2.3.1 Rising geriatric patient pool to drive market growth 171
12.3 EUROPE 175
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 175
12.3.2 GERMANY 179
12.3.2.1 Increasing healthcare expenditure to drive market growth 179
12.3.3 UK 182
12.3.3.1 Rising adoption of advanced healthcare systems to support market growth 182
12.3.4 FRANCE 186
12.3.4.1 Rising digital expansion to propel market growth 186
12.3.5 ITALY 190
12.3.5.1 Rising elderly patient pool to drive market growth 190
12.3.6 SPAIN 193
12.3.6.1 Steady modernization of healthcare system in Spain to support market growth 193
12.3.7 NETHERLANDS 197
12.3.7.1 Strong healthcare infrastructure and aging population to drive market 197
12.3.8 DENMARK 200
12.3.8.1 Well-established healthcare infrastructure to boost market 200
12.3.9 SWEDEN 203
12.3.9.1 Rising healthcare expenditure to aid market growth 203
12.3.10 REST OF EUROPE 206
12.4 ASIA PACIFIC 210
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 210
12.4.2 CHINA 215
12.4.2.1 Government support and rising disease burden to drive market growth 215
12.4.3 JAPAN 219
12.4.3.1 High healthcare expenditure, favorable reimbursement, and insurance coverage to support market growth 219
12.4.4 INDIA 223
12.4.4.1 Government initiatives to propel market growth 223
12.4.5 SOUTH KOREA 227
12.4.5.1 Rising aging population to bolster market growth 227
12.4.6 AUSTRALIA 230
12.4.6.1 Rising hospitalization rates to aid market growth 230
12.4.7 PHILIPPINES 234
12.4.7.1 Government investment and public hospital modernization to fuel demand 234
12.4.8 MALAYSIA 238
12.4.8.1 Rising healthcare investment and technological advancements to drive market 238
12.4.9 VIETNAM 241
12.4.9.1 Growing aging population and healthcare infrastructure development to fuel market 241
12.4.10 SINGAPORE 245
12.4.10.1 Advanced healthcare infrastructure and technological integration to boost market 245
12.4.11 INDONESIA 249
12.4.11.1 Rising prevalence of chronic diseases to drive market 249
12.4.12 THAILAND 253
12.4.12.1 Rising geriatric population and chronic diseases to drive market 253
12.4.13 REST OF ASIA PACIFIC 257
12.5 LATIN AMERICA 260
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 261
12.5.2 BRAZIL 264
12.5.2.1 Favorable government initiatives to propel market growth 264
12.5.3 MEXICO 268
12.5.3.1 Rising disease burden to aid market growth 268
12.5.4 ARGENTINA 272
12.5.4.1 Rapid aging population and subsequent rise in chronic diseases to boost market 272
12.5.5 COLOMBIA 276
12.5.5.1 Integration of technological advancements in hospitals & infusion therapy settings to propel market 276
12.5.6 CHILE 280
12.5.6.1 Growing focus on local infusion-therapy product manufacturers to fuel uptake 280
12.5.7 ECUADOR 284
12.5.7.1 Digital health initiatives to support market growth 284
12.5.8 PERU 288
12.5.8.1 Increasing focus on oncology therapeutics to boost market 288
12.5.9 REST OF LATIN AMERICA 292
12.6 MIDDLE EAST & AFRICA 295
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 296
12.6.2 GCC COUNTRIES 300
12.6.2.1 Kingdom of Saudi Arabia (KSA) 303
12.6.2.1.1 Favorable government initiatives to boost growth 303
12.6.2.2 United Arab Emirates (UAE) 307
12.6.2.2.1 Government strategies to drive market in UAE 307
12.6.2.3 Rest of GCC countries 311
12.6.3 REST OF MIDDLE EAST & AFRICA 314
13 COMPETITIVE LANDSCAPE 319
13.1 OVERVIEW 319
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 319
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS 319
13.3 REVENUE ANALYSIS, 2023–2025 321
13.4 GLOBAL MARKET SHARE ANALYSIS, 2025 321
13.4.1 US MARKET SHARE ANALYSIS, 2025 323
13.4.2 EUROPE MARKET SHARE ANALYSIS, 2025 323
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 324
13.5.1 STARS 324
13.5.2 EMERGING LEADERS 324
13.5.3 PERVASIVE PLAYERS 325
13.5.4 PARTICIPANTS 325
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 326
13.5.5.1 Company footprint 326
13.5.5.2 Region footprint 326
13.5.5.3 Type footprint 327
13.5.5.4 Application footprint 328
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 328
13.6.1 PROGRESSIVE COMPANIES 328
13.6.2 RESPONSIVE COMPANIES 328
13.6.3 DYNAMIC COMPANIES 329
13.6.4 STARTING BLOCKS 329
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 330
13.6.5.1 Detailed list of key startups/SMEs 330
13.6.5.2 Competitive benchmarking of key startups/SME players 330
13.7 COMPANY VALUATION & FINANCIAL METRICS 331
13.7.1 FINANCIAL METRICS 331
13.7.2 COMPANY VALUATION 331
13.8 BRAND/PRODUCT COMPARISON 332
13.9 COMPETITIVE SCENARIO 333
13.9.1 PRODUCT LAUNCHES & APPROVALS 333
13.9.2 DEALS 334
13.9.3 EXPANSIONS 335
13.9.4 OTHER DEVELOPMENTS 335
14 COMPANY PROFILES 336
14.1 KEY PLAYERS 336
14.1.1 BECTON, DICKINSON AND COMPANY 336
14.1.1.1 Business overview 336
14.1.1.2 Products offered 337
14.1.1.3 Recent developments 339
14.1.1.3.1 Product approvals 339
14.1.1.3.2 Deals 340
14.1.1.3.3 Expansions 340
14.1.1.3.4 Other developments 341
14.1.1.4 MnM view 341
14.1.1.4.1 Right to win 341
14.1.1.4.2 Strategic choices 341
14.1.1.4.3 Weaknesses & competitive threats 341
14.1.2 B. BRAUN SE 342
14.1.2.1 Business overview 342
14.1.2.2 Products offered 343
14.1.2.3 Recent developments 347
14.1.2.3.1 Product launches & approvals 347
14.1.2.3.2 Deals 347
14.1.2.4 MnM view 348
14.1.2.4.1 Right to win 348
14.1.2.4.2 Strategic choices 348
14.1.2.4.3 Weaknesses & competitive threats 348
14.1.3 BAXTER 349
14.1.3.1 Business overview 349
14.1.3.2 Products offered 350
14.1.3.3 Recent developments 351
14.1.3.3.1 Product approvals 351
14.1.3.3.2 Deals 352
14.1.3.4 MnM view 352
14.1.3.4.1 Right to win 352
14.1.3.4.2 Strategic choices 352
14.1.3.4.3 Weaknesses & competitive threats 353
14.1.4 FRESENIUS SE & CO. KGAA 354
14.1.4.1 Business overview 354
14.1.4.2 Products offered 355
14.1.4.3 Recent developments 357
14.1.4.3.1 Product approvals 357
14.1.4.3.2 Deals 357
14.1.4.4 MnM view 358
14.1.4.4.1 Right to win 358
14.1.4.4.2 Strategic choices 358
14.1.4.4.3 Weaknesses & competitive threats 358
14.1.5 ICU MEDICAL, INC. 359
14.1.5.1 Business overview 359
14.1.5.2 Products offered 360
14.1.5.3 Recent developments 362
14.1.5.3.1 Product approvals 362
14.1.5.3.2 Deals 362
14.1.5.4 MnM view 363
14.1.5.4.1 Right to win 363
14.1.5.4.2 Strategic choices 363
14.1.5.4.3 Weaknesses & competitive threats 363
14.1.6 TERUMO CORPORATION 364
14.1.6.1 Business overview 364
14.1.6.2 Products offered 365
14.1.6.3 Recent developments 366
14.1.6.3.1 Deals 366
14.1.6.3.2 Expansions 366

14.1.7 MOOG, INC. 367
14.1.7.1 Business overview 367
14.1.7.2 Products offered 368
14.1.7.2.1 Product approvals 369
14.1.8 TELEFLEX INCORPORATED 370
14.1.8.1 Business overview 370
14.1.8.2 Products offered 371
14.1.9 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 372
14.1.9.1 Business overview 372
14.1.9.2 Products offered 373
14.1.9.3 Recent developments 374
14.1.9.3.1 Product launches 374
14.1.9.3.2 Other developments 375
14.1.10 CARDINAL HEALTH 376
14.1.10.1 Business overview 376
14.1.10.2 Products offered 377
14.1.10.3 Recent developments 378
14.1.10.3.1 Expansions 378
14.1.11 AVANOS MEDICAL, INC. 379
14.1.11.1 Business overview 379
14.1.11.2 Products offered 380
14.1.12 NIPRO 381
14.1.12.1 Business overview 381
14.1.12.2 Products offered 382
14.1.12.3 Recent developments 383
14.1.12.3.1 Expansions 383
14.1.13 JMS CO., LTD. 384
14.1.13.1 Business overview 384
14.1.13.2 Products offered 385
14.1.14 VYGON 386
14.1.14.1 Business overview 386
14.1.14.2 Products offered 386
14.1.14.3 Recent developments 387
14.1.14.3.1 Deals 387
14.1.15 MICREL MEDICAL DEVICES SA 388
14.1.15.1 Business overview 388
14.1.15.2 Products offered 388
14.1.15.3 Recent developments 389
14.1.15.3.1 Deals 389
14.2 OTHER PLAYERS 390
14.2.1 ARCOMED 390
14.2.2 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD. 391
14.2.3 EITAN MEDICAL 392
14.2.4 ANGIPLAST PRIVATE LIMITED 393
14.2.5 PRIMEGUARD MEDICAL 394
14.2.6 IRADIMED CORPORATION 395
14.2.7 EPIC MEDICAL 395
14.2.8 ROMSONS 396
14.2.9 BEIJING KELLYMED CO., LTD. 397
14.2.10 INTUVIE HOLDINGS LLC 398
14.2.11 PROMED TECHNOLOGY CO., LIMITED 399
14.2.12 MEDCAPTAIN MEDICAL TECHNOLOGY CO., LTD. 400
15 RESEARCH METHODOLOGY 401
15.1 RESEARCH APPROACH 401
15.2 RESEARCH METHODOLOGY DESIGN 401
15.2.1 SECONDARY RESEARCH 402
15.2.1.1 Key data from secondary sources 403
15.2.2 PRIMARY DATA 403
15.2.2.1 Key industry insights 404
15.3 MARKET SIZE ESTIMATION 406
15.3.1 BOTTOM-UP APPROACH 411
15.4 MARKET BREAKDOWN & DATA TRIANGULATION 412
15.5 MARKET SHARE ESTIMATION 413
15.6 ASSUMPTIONS 413
15.6.1 GROWTH RATE ASSUMPTIONS 414
15.7 RISK ASSESSMENT 414
15.8 LIMITATIONS 414
15.8.1 METHODOLOGY-RELATED LIMITATIONS 414
15.8.2 SCOPE-RELATED LIMITATIONS 414
16 APPENDIX 415
16.1 DISCUSSION GUIDE 415
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 420
16.3 CUSTOMIZATION OPTIONS 422
16.3.1 COMPANY INFORMATION 422
16.3.2 GEOGRAPHIC ANALYSIS 422
16.3.3 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS 422
16.3.4 COUNTRY-LEVEL VOLUME ANALYSIS 422
16.3.5 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST 422
16.4 RELATED REPORTS 423
16.5 AUTHOR DETAILS 424

LIST OF TABLES

TABLE 1 IV EQUIPMENT MARKET: INCLUSIONS & EXCLUSIONS 36
TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 37
TABLE 3 IV EQUIPMENT MARKET: PORTER’S FIVE FORCES ANALYSIS 57
TABLE 4 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION) 60
TABLE 5 IV EQUIPMENT MARKET: ROLE IN ECOSYSTEM 65
TABLE 6 AVERAGE SELLING PRICE TREND OF IV EQUIPMENT, BY KEY PLAYER,
2023–2025 (USD) 66
TABLE 7 AVERAGE SELLING PRICE TREND OF INFUSION PUMPS, BY REGION,
2023–2025 (USD) 67
TABLE 8 IMPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN MEDICAL, SURGICAL, OR VETERINARY SCIENCES (HS CODE 901890), BY COUNTRY,
2020–2024 (USD THOUSAND) 68
TABLE 9 EXPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN MEDICAL, SURGICAL, OR VETERINARY SCIENCES (HS CODE 901890), BY COUNTRY,
2020–2024 (USD THOUSAND) 69
TABLE 10 IV EQUIPMENT MARKET: MAJOR CONFERENCES & EVENTS IN 2026–2027 70
TABLE 11 CASE STUDY 1: NEXT-GENERATION INTRAVENOUS (IV) INFUSION PUMPS 73
TABLE 12 CASE STUDY 2: PREVENTING IV CATHETER DISLODGMENT IN PEDIATRIC NEUROSURGERY 73
TABLE 13 CASE STUDY 3: INFUSION PUMP INTEROPERABILITY TRANSFORMS MEDICATION SAFETY 74
TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES, 2024 76
TABLE 15 KEY PRODUCT-RELATED TARIFFS EFFECTIVE 76
TABLE 16 NORTH AMERICA: IMPACT OF US TARIFFS ON CANADA 77
TABLE 17 ASIA PACIFIC: IMPACT OF US TARIFFS ON CHINA, JAPAN, AND INDIA 77
TABLE 18 EUROPE: IMPACT OF US TARIFFS ON GERMANY AND UK 78
TABLE 19 LATIN AMERICA: IMPACT OF US TARIFFS ON MEXICO 79
TABLE 20 IV EQUIPMENT MARKET: KEY PATENTS, 2023–2025 84
TABLE 21 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 22 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 23 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 24 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 25 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 26 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF IV EQUIPMENT 97
TABLE 27 KEY BUYING CRITERIA FOR IV EQUIPMENT, BY TYPE 98
TABLE 28 IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 102
TABLE 29 COMMERCIAL IV CATHETERS AVAILABLE IN MARKET 103
TABLE 30 IV CATHETERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 103
TABLE 31 COMMERCIAL INFUSION PUMPS AVAILABLE IN MARKET 105
TABLE 32 INFUSION PUMPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 105
TABLE 33 COMMERCIAL IV ADMINISTRATION SETS & TUBING AVAILABLE IN MARKET 107
TABLE 34 IV ADMINISTRATION SETS & TUBING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 107
TABLE 35 COMMERCIAL SECUREMENT & STABILIZATION DEVICES AVAILABLE IN MARKET 109
TABLE 36 SECUREMENT & STABILIZATION DEVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 109
TABLE 37 COMMERCIAL NEEDLE-FREE CONNECTORS & EXTENSION SETS AVAILABLE IN MARKET 111
TABLE 38 NEEDLE-FREE CONNECTORS & EXTENSION SETS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 111
TABLE 39 COMMERCIAL IV DRIP CHAMBERS AVAILABLE IN MARKET 113
TABLE 40 IV DRIP CHAMBERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 113
TABLE 41 COMMERCIAL OTHER IV EQUIPMENT AVAILABLE IN MARKET 115
TABLE 42 OTHER IV EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 115
TABLE 43 IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 118
TABLE 44 IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE,
2024–2031 (USD MILLION) 119
TABLE 45 IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY COUNTRY,
2024–2031 (USD MILLION) 119
TABLE 46 IV EQUIPMENT MARKET FOR ONCOLOGY (IV CHEMOTHERAPY), BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 47 IV EQUIPMENT MARKET FOR ANTIBIOTIC/ANTIMICROBIAL IV THERAPY,
BY COUNTRY, 2024–2031 (USD MILLION) 122
TABLE 48 IV EQUIPMENT MARKET FOR CRITICAL CARE & VASOACTIVE DRUG INFUSION,
BY COUNTRY, 2024–2031 (USD MILLION) 124
TABLE 49 IV EQUIPMENT MARKET FOR ANALGESIA/PAIN MANAGEMENT, BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 50 IV EQUIPMENT MARKET FOR SEDATION & ANESTHESIA INFUSION, BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 51 IV EQUIPMENT MARKET FOR IMMUNOTHERAPY, BY COUNTRY,
2024–2031 (USD MILLION) 129
TABLE 52 IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION (PN), BY TYPE,
2024–2031 (USD MILLION) 130
TABLE 53 IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION (PN), BY COUNTRY,
2024–2031 (USD MILLION) 131
TABLE 54 IV EQUIPMENT MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 55 IV EQUIPMENT MARKET FOR CRITICAL CARE NUTRITION, BY COUNTRY,
2024–2031 (USD MILLION) 134
TABLE 56 IV EQUIPMENT MARKET FOR NEONATAL & PEDIATRIC PARENTERAL NUTRITION,
BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 57 IV EQUIPMENT MARKET FOR OTHER PARENTERAL NUTRITION APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 58 IV EQUIPMENT MARKET FOR FLUID & ELECTROLYTE REPLACEMENT, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 59 IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 140
TABLE 60 IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 61 IV EQUIPMENT MARKET FOR RED BLOOD CELL TRANSFUSION, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 62 IV EQUIPMENT MARKET FOR PLATELET TRANSFUSION, BY COUNTRY,
2024–2031 (USD MILLION) 143
TABLE 63 IV EQUIPMENT MARKET FOR PLASMA TRANSFUSION, BY COUNTRY,
2024–2031 (USD MILLION) 145
TABLE 64 IV EQUIPMENT MARKET FOR OTHER BLOOD & BLOOD PRODUCTS TRANSFUSION APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 65 IV EQUIPMENT MARKET FOR DIAGNOSTIC TESTING, BY COUNTRY,
2024–2031 (USD MILLION) 148
TABLE 66 IV EQUIPMENT MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 149
TABLE 67 IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 152
TABLE 68 IV EQUIPMENT MARKET FOR HOSPITALS, BY COUNTRY,
2024–2031 (USD MILLION) 153
TABLE 69 IV EQUIPMENT MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 70 IV EQUIPMENT MARKET FOR OUTPATIENT INFUSION & SPECIALTY CLINICS,
BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 71 IV EQUIPMENT MARKET FOR HOME CARE SETTINGS, BY COUNTRY,
2024–2031 (USD MILLION) 157
TABLE 72 IV EQUIPMENT MARKET FOR OTHER END USERS, BY COUNTRY,
2024–2031 (USD MILLION) 159
TABLE 73 IV EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 162
TABLE 74 IV CATHETERS MARKET, BY REGION, 2024–2031 (MILLION UNITS) 162
TABLE 75 INFUSION PUMPS MARKET, BY REGION, 2024–2031 (MILLION UNITS) 163
TABLE 76 IV ADMINISTRATION SETS & TUBING MARKET, BY REGION,
2024–2031 (MILLION UNITS) 163
TABLE 77 NORTH AMERICA: IV EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 165
TABLE 78 NORTH AMERICA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 165
TABLE 79 NORTH AMERICA: IV EQUIPMENT MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 166
TABLE 80 NORTH AMERICA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 166
TABLE 81 NORTH AMERICA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 167
TABLE 82 NORTH AMERICA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 167
TABLE 83 NORTH AMERICA: IV EQUIPMENT MARKET, BY END USER,
2024–2031 (USD MILLION) 168
TABLE 84 US: KEY MACROECONOMIC INDICATORS 168
TABLE 85 US: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 169
TABLE 86 US: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 169
TABLE 87 US: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE,
2024–2031 (USD MILLION) 170
TABLE 88 US: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 170
TABLE 89 US: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION,
BY TYPE, 2024–2031 (USD MILLION) 171
TABLE 90 US: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 171
TABLE 91 CANADA: KEY MACROECONOMIC INDICATORS 172
TABLE 92 CANADA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 172
TABLE 93 CANADA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 173
TABLE 94 CANADA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 173
TABLE 95 CANADA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 174
TABLE 96 CANADA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 174
TABLE 97 CANADA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 175
TABLE 98 EUROPE: IV EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 99 EUROPE: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 176
TABLE 100 EUROPE: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 177
TABLE 101 EUROPE: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 177
TABLE 102 EUROPE: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 178
TABLE 103 EUROPE: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 178
TABLE 104 EUROPE: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 179
TABLE 105 GERMANY: KEY MACROECONOMIC INDICATORS 179
TABLE 106 GERMANY: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 180
TABLE 107 GERMANY: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 180
TABLE 108 GERMANY: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 181
TABLE 109 GERMANY: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 181
TABLE 110 GERMANY: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 182
TABLE 111 GERMANY: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 182
TABLE 112 UK: KEY MACROECONOMIC INDICATORS 183
TABLE 113 UK: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 184
TABLE 114 UK: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 184
TABLE 115 UK: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE,
2024–2031 (USD MILLION) 185
TABLE 116 UK: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 185
TABLE 117 UK: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION,
BY TYPE, 2024–2031 (USD MILLION) 186
TABLE 118 UK: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 186
TABLE 119 FRANCE: KEY MACROECONOMIC INDICATORS 187
TABLE 120 FRANCE: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 187
TABLE 121 FRANCE : IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 188
TABLE 122 FRANCE : IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 188
TABLE 123 FRANCE: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 189
TABLE 124 FRANCE: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 189
TABLE 125 FRANCE: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 190
TABLE 126 ITALY: KEY MACROECONOMIC INDICATORS 190
TABLE 127 ITALY: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 191
TABLE 128 ITALY: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 191
TABLE 129 ITALY: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 192
TABLE 130 ITALY: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 192
TABLE 131 ITALY: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 193
TABLE 132 ITALY: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 193
TABLE 133 SPAIN: KEY MACROECONOMIC INDICATORS 194
TABLE 134 SPAIN: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 194
TABLE 135 SPAIN: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 195
TABLE 136 SPAIN: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 195
TABLE 137 SPAIN: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 196
TABLE 138 SPAIN: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 196
TABLE 139 SPAIN: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 197
TABLE 140 NETHERLANDS: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 198
TABLE 141 NETHERLANDS: IV EQUIPMENT MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 198
TABLE 142 NETHERLANDS: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 199
TABLE 143 NETHERLANDS: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 199
TABLE 144 NETHERLANDS: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 200
TABLE 145 NETHERLANDS: IV EQUIPMENT MARKET, BY END USER,
2024–2031 (USD MILLION) 200
TABLE 146 DENMARK: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 201
TABLE 147 DENMARK: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 201
TABLE 148 DENMARK: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 202
TABLE 149 DENMARK: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 202
TABLE 150 DENMARK: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 203
TABLE 151 DENMARK: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 203
TABLE 152 SWEDEN: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 204
TABLE 153 SWEDEN: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 204
TABLE 154 SWEDEN: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 205
TABLE 155 SWEDEN: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 205
TABLE 156 SWEDEN: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 206
TABLE 157 SWEDEN: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 206
TABLE 158 REST OF EUROPE: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 207
TABLE 159 REST OF EUROPE: IV EQUIPMENT MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 207
TABLE 160 REST OF EUROPE: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 208
TABLE 161 REST OF EUROPE: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 208
TABLE 162 REST OF EUROPE: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 209
TABLE 163 REST OF EUROPE: IV EQUIPMENT MARKET, BY END USER,
2024–2031 (USD MILLION) 209
TABLE 164 ASIA PACIFIC: IV EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 165 ASIA PACIFIC: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 212
TABLE 166 ASIA PACIFIC: IV EQUIPMENT MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 213
TABLE 167 ASIA PACIFIC: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 213
TABLE 168 ASIA PACIFIC: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 214
TABLE 169 ASIA PACIFIC: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 214
TABLE 170 ASIA PACIFIC: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 215
TABLE 171 CHINA: KEY MACROECONOMIC INDICATORS 216
TABLE 172 CHINA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 216
TABLE 173 CHINA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 217
TABLE 174 CHINA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 217
TABLE 175 CHINA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 218
TABLE 176 CHINA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 218
TABLE 177 CHINA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 219
TABLE 178 JAPAN: KEY MACROECONOMIC INDICATORS 220
TABLE 179 JAPAN: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 220
TABLE 180 JAPAN: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 221
TABLE 181 JAPAN: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 221
TABLE 182 JAPAN: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 222
TABLE 183 JAPAN: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 222
TABLE 184 JAPAN: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 223
TABLE 185 INDIA: KEY MACROECONOMIC INDICATORS 224
TABLE 186 INDIA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 224
TABLE 187 INDIA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 225
TABLE 188 INDIA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 225
TABLE 189 INDIA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 226
TABLE 190 INDIA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 226
TABLE 191 INDIA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 227
TABLE 192 SOUTH KOREA: KEY MACROECONOMIC INDICATORS 227
TABLE 193 SOUTH KOREA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 228
TABLE 194 SOUTH KOREA: IV EQUIPMENT MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 228
TABLE 195 SOUTH KOREA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 229
TABLE 196 SOUTH KOREA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 229
TABLE 197 SOUTH KOREA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 230
TABLE 198 SOUTH KOREA: IV EQUIPMENT MARKET, BY END USER,
2024–2031 (USD MILLION) 230
TABLE 199 AUSTRALIA: KEY MACROECONOMIC INDICATORS 231
TABLE 200 AUSTRALIA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 231
TABLE 201 AUSTRALIA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 232
TABLE 202 AUSTRALIA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 232
TABLE 203 AUSTRALIA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 233
TABLE 204 AUSTRALIA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 233
TABLE 205 AUSTRALIA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 234
TABLE 206 PHILIPPINES: KEY MACROECONOMIC INDICATORS 235
TABLE 207 PHILIPPINES: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 235
TABLE 208 PHILIPPINES: IV EQUIPMENT MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 236
TABLE 209 PHILIPPINES: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION,
BY TYPE, 2024–2031 (USD MILLION) 236
TABLE 210 PHILIPPINES: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 237
TABLE 211 PHILIPPINES: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 237
TABLE 212 PHILIPPINES: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 238
TABLE 213 MALAYSIA: KEY MACROECONOMIC INDICATORS 238
TABLE 214 MALAYSIA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 239
TABLE 215 MALAYSIA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 239
TABLE 216 MALAYSIA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 240
TABLE 217 MALAYSIA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 240
TABLE 218 MALAYSIA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 241
TABLE 219 MALAYSIA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 241
TABLE 220 VIETNAM: KEY MACROECONOMIC INDICATORS 242
TABLE 221 VIETNAM: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 242
TABLE 222 VIETNAM: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 243
TABLE 223 VIETNAM: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 243
TABLE 224 VIETNAM: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 244
TABLE 225 VIETNAM: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 244
TABLE 226 VIETNAM: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 245
TABLE 227 SINGAPORE: KEY MACROECONOMIC INDICATORS 246
TABLE 228 SINGAPORE: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 229 SINGAPORE: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 247
TABLE 230 SINGAPORE: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 247
TABLE 231 SINGAPORE: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 232 SINGAPORE: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 233 SINGAPORE: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 249
TABLE 234 INDONESIA: KEY MACROECONOMIC INDICATORS 250
TABLE 235 INDONESIA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 250
TABLE 236 INDONESIA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 251
TABLE 237 INDONESIA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 251
TABLE 238 INDONESIA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 252
TABLE 239 INDONESIA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 252
TABLE 240 INDONESIA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 253
TABLE 241 THAILAND: KEY MACROECONOMIC INDICATORS 254
TABLE 242 THAILAND: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 254
TABLE 243 THAILAND: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 255
TABLE 244 THAILAND: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 255
TABLE 245 THAILAND: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 256
TABLE 246 THAILAND: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 256
TABLE 247 THAILAND: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 257
TABLE 248 REST OF ASIA PACIFIC: IV EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 258
TABLE 249 REST OF ASIA PACIFIC: IV EQUIPMENT MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 258
TABLE 250 REST OF ASIA PACIFIC: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 259
TABLE 251 REST OF ASIA PACIFIC: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION,
BY TYPE, 2024–2031 (USD MILLION) 259
TABLE 252 REST OF ASIA PACIFIC: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 260
TABLE 253 REST OF ASIA PACIFIC: IV EQUIPMENT MARKET, BY END USER,
2024–2031 (USD MILLION) 260
TABLE 254 LATIN AMERICA: IV EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 261
TABLE 255 LATIN AMERICA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 262
TABLE 256 LATIN AMERICA: IV EQUIPMENT MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 262
TABLE 257 LATIN AMERICA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION,
BY TYPE, 2024–2031 (USD MILLION) 263
TABLE 258 LATIN AMERICA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 263
TABLE 259 LATIN AMERICA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 264
TABLE 260 LATIN AMERICA: IV EQUIPMENT MARKET, BY END USER,
2024–2031 (USD MILLION) 264
TABLE 261 BRAZIL: KEY MACROECONOMIC INDICATORS 265
TABLE 262 BRAZIL: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 265
TABLE 263 BRAZIL: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 266
TABLE 264 BRAZIL: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 266
TABLE 265 BRAZIL: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 267
TABLE 266 BRAZIL: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 267
TABLE 267 BRAZIL: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 268
TABLE 268 MEXICO: KEY MACROECONOMIC INDICATORS 269
TABLE 269 MEXICO: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 269
TABLE 270 MEXICO: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 270
TABLE 271 MEXICO: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 270
TABLE 272 MEXICO: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 271
TABLE 273 MEXICO: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 271
TABLE 274 MEXICO: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 272
TABLE 275 ARGENTINA: KEY MACROECONOMIC INDICATORS 273
TABLE 276 ARGENTINA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 273
TABLE 277 ARGENTINA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 274
TABLE 278 ARGENTINA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 274
TABLE 279 ARGENTINA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 275
TABLE 280 ARGENTINA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 275
TABLE 281 ARGENTINA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 276
TABLE 282 COLOMBIA: KEY MACROECONOMIC INDICATORS 277
TABLE 283 COLOMBIA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 277
TABLE 284 COLOMBIA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 278
TABLE 285 COLOMBIA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 278
TABLE 286 COLOMBIA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 279
TABLE 287 COLOMBIA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 279
TABLE 288 COLOMBIA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 280
TABLE 289 CHILE: KEY MACROECONOMIC INDICATORS 281
TABLE 290 CHILE: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 281
TABLE 291 CHILE: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 282
TABLE 292 CHILE: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 282
TABLE 293 CHILE: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 283
TABLE 294 CHILE: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 283
TABLE 295 CHILE: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 284
TABLE 296 ECUADOR: KEY MACROECONOMIC INDICATORS 285
TABLE 297 ECUADOR: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 285
TABLE 298 ECUADOR: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 286
TABLE 299 ECUADOR: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 286
TABLE 300 ECUADOR: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 287
TABLE 301 ECUADOR: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 287
TABLE 302 ECUADOR: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 288
TABLE 303 PERU: KEY MACROECONOMIC INDICATORS 289
TABLE 304 PERU: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 289
TABLE 305 PERU: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 290
TABLE 306 PERU: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 290
TABLE 307 PERU: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 291
TABLE 308 PERU: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 291
TABLE 309 PERU: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 292
TABLE 310 REST OF LATIN AMERICA: IV EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 293
TABLE 311 REST OF LATIN AMERICA: IV EQUIPMENT MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 293
TABLE 312 REST OF LATIN AMERICA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 294
TABLE 313 REST OF LATIN AMERICA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 294
TABLE 314 REST OF LATIN AMERICA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 295
TABLE 315 REST OF LATIN AMERICA: IV EQUIPMENT MARKET, BY END USER,
2024–2031 (USD MILLION) 295
TABLE 316 MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET, BY REGION,
2024–2031 (USD MILLION) 297
TABLE 317 MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 297
TABLE 318 MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 298
TABLE 319 MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 298
TABLE 320 MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION,
BY TYPE, 2024–2031 (USD MILLION) 299
TABLE 321 MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 299
TABLE 322 MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET, BY END USER,
2024–2031 (USD MILLION) 300
TABLE 323 GCC COUNTRIES: IV EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 300
TABLE 324 GCC COUNTRIES: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 301
TABLE 325 GCC COUNTRIES: IV EQUIPMENT MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 301
TABLE 326 GCC COUNTRIES: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 302
TABLE 327 GCC COUNTRIES: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 302
TABLE 328 GCC COUNTRIES: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 303
TABLE 329 GCC COUNTRIES: IV EQUIPMENT MARKET, BY END USER,
2024–2031 (USD MILLION) 303
TABLE 330 KINGDOM OF SAUDI ARABIA: KEY MACROECONOMIC INDICATORS 304
TABLE 331 KINGDOM OF SAUDI ARABIA: IV EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 305
TABLE 332 KINGDOM OF SAUDI ARABIA: IV EQUIPMENT MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 305
TABLE 333 KINGDOM OF SAUDI ARABIA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 306
TABLE 334 KINGDOM OF SAUDI ARABIA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 306
TABLE 335 KINGDOM OF SAUDI ARABIA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 307
TABLE 336 KINGDOM OF SAUDI ARABIA: IV EQUIPMENT MARKET, BY END USER,
2024–2031 (USD MILLION) 307
TABLE 337 UAE: KEY MACROECONOMIC INDICATORS 308
TABLE 338 UAE: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 308
TABLE 339 UAE: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 309
TABLE 340 UAE: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE,
2024–2031 (USD MILLION) 309
TABLE 341 UAE: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE,
2024–2031 (USD MILLION) 310
TABLE 342 UAE: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION,
BY TYPE, 2024–2031 (USD MILLION) 310
TABLE 343 UAE: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 311
TABLE 344 REST OF GCC COUNTRIES: IV EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 312
TABLE 345 REST OF GCC COUNTRIES: IV EQUIPMENT MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 312
TABLE 346 REST OF GCC COUNTRIES: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 313
TABLE 347 REST OF GCC COUNTRIES: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 313
TABLE 348 REST OF GCC COUNTRIES: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 314
TABLE 349 REST OF GCC COUNTRIES: IV EQUIPMENT MARKET, BY END USER,
2024–2031 (USD MILLION) 314
TABLE 350 REST OF MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 315
TABLE 351 REST OF MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 316
TABLE 352 REST OF MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 316
TABLE 353 REST OF MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 317
TABLE 354 REST OF MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 317
TABLE 355 REST OF MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET, BY END USER,
2024–2031 (USD MILLION) 318
TABLE 356 OVERVIEW OF STRATEGIES ADOPTED BY KEY IV EQUIPMENT MANUFACTURING COMPANIES 319
TABLE 357 GLOBAL IV EQUIPMENT MARKET: DEGREE OF COMPETITION 322
TABLE 358 IV EQUIPMENT MARKET: REGION FOOTPRINT 326
TABLE 359 IV EQUIPMENT MARKET: TYPE FOOTPRINT 327
TABLE 360 IV EQUIPMENT MARKET: APPLICATION FOOTPRINT 328
TABLE 361 IV EQUIPMENT MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 330
TABLE 362 IV EQUIPMENT MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS 330
TABLE 363 IV EQUIPMENT MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–DECEMBER 2025 333
TABLE 364 IV EQUIPMENT MARKET: DEALS, JANUARY 2022–DECEMBER 2025 334
TABLE 365 IV EQUIPMENT MARKET: EXPANSIONS, JANUARY 2022–DECEMBER 2025 335
TABLE 366 IV EQUIPMENT MARKET: OTHER DEVELOPMENTS,
JANUARY 2022–DECEMBER 2025 335
TABLE 367 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 336
TABLE 368 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 337
TABLE 369 BECTON, DICKINSON AND COMPANY: PRODUCT APPROVALS,
JANUARY 2022–DECEMBER 2025 339
TABLE 370 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2022–DECEMBER 2025 340
TABLE 371 BECTON, DICKINSON AND COMPANY: EXPANSIONS,
JANUARY 2022–DECEMBER 2025 340
TABLE 372 BECTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS,
JANUARY 2022–DECEMBER 2025 341
TABLE 373 B. BRAUN SE: COMPANY OVERVIEW 342
TABLE 374 B. BRAUN SE: PRODUCTS OFFERED 343
TABLE 375 B. BRAUN SE: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–NOVEMBER 2025 347
TABLE 376 B. BRAUN SE: DEALS, JANUARY 2022−DECEMBER 2025 347
TABLE 377 BAXTER: COMPANY OVERVIEW 349
TABLE 378 BAXTER: PRODUCTS OFFERED 350
TABLE 379 BAXTER: PRODUCT APPROVALS, JANUARY 2022−NOVEMBER 2025 351
TABLE 380 BAXTER: DEALS, JANUARY 2022−NOVEMBER 2025 352
TABLE 381 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW 354
TABLE 382 FRESENIUS SE & CO. KGAA: PRODUCTS OFFERED 355
TABLE 383 FRESENIUS SE & CO. KGAA: PRODUCT APPROVALS,
JANUARY 2022–DECEMBER 2025 357
TABLE 384 FRESENIUS SE & CO. KGAA: DEALS, JANUARY 2022–DECEMBER 2025 357
TABLE 385 ICU MEDICAL, INC.: COMPANY OVERVIEW 359
TABLE 386 ICU MEDICAL, INC.: PRODUCTS OFFERED 360
TABLE 387 ICU MEDICAL, INC.: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 362
TABLE 388 ICU MEDICAL, INC.: DEALS, JANUARY 2022–DECEMBER 2025 362
TABLE 389 TERUMO CORPORATION: COMPANY OVERVIEW 364
TABLE 390 TERUMO CORPORATION: PRODUCTS OFFERED 365
TABLE 391 TERUMO CORPORATION: DEALS, JANUARY 2022–DECEMBER 2025 366
TABLE 392 TERUMO CORPORATION: EXPANSIONS, JANUARY 2022–DECEMBER 2025 366
TABLE 393 MOOG INC.: COMPANY OVERVIEW 367
TABLE 394 MOOG INC.: PRODUCTS OFFERED 368
TABLE 395 MOOG INC.: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 369
TABLE 396 TELEFLEX INCORPORATED: COMPANY OVERVIEW 370
TABLE 397 TELEFLEX INCORPORATED: PRODUCTS OFFERED 371
TABLE 398 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW 372
TABLE 399 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED 373
TABLE 400 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025 374
TABLE 401 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 375
TABLE 402 CARDINAL HEALTH: COMPANY OVERVIEW 376
TABLE 403 CARDINAL HEALTH: PRODUCTS OFFERED 377
TABLE 404 CARDINAL HEALTH: EXPANSIONS, JANUARY 2022–DECEMBER 2025 378
TABLE 405 AVANOS MEDICAL, INC.: COMPANY OVERVIEW 379
TABLE 406 AVANOS MEDICAL, INC.: PRODUCTS OFFERED 380
TABLE 407 NIPRO: COMPANY OVERVIEW 381
TABLE 408 NIPRO: PRODUCTS OFFERED 382
TABLE 409 NIPRO: EXPANSIONS, JANUARY 2022–DECEMBER 2025 383
TABLE 410 JMS CO., LTD.: COMPANY OVERVIEW 384
TABLE 411 JMS CO., LTD.: PRODUCTS OFFERED 385
TABLE 412 VYGON: COMPANY OVERVIEW 386
TABLE 413 VYGON: PRODUCTS OFFERED 386
TABLE 414 VYGON: DEALS, JANUARY 2022–DECEMBER 2025 387
TABLE 415 MICREL MEDICAL DEVICES SA: COMPANY OVERVIEW 388
TABLE 416 MICREL MEDICAL DEVICES SA: PRODUCTS OFFERED 388
TABLE 417 MICREL MEDICAL DEVICES SA: DEALS, JANUARY 2022–DECEMBER 2025 389
TABLE 418 ARCOMED: COMPANY OVERVIEW 390
TABLE 419 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.: COMPANY OVERVIEW 391
TABLE 420 EITAN MEDICAL: COMPANY OVERVIEW 392
TABLE 421 ANGIPLAST PRIVATE LIMITED: COMPANY OVERVIEW 393
TABLE 422 PRIMEGUARD MEDICAL: COMPANY OVERVIEW 394
TABLE 423 IRADIMED CORPORATION: COMPANY OVERVIEW 395
TABLE 424 EPIC MEDICAL: COMPANY OVERVIEW 395
TABLE 425 ROMSONS: COMPANY OVERVIEW 396
TABLE 426 BEIJING KELLYMED CO., LTD.: COMPANY OVERVIEW 397
TABLE 427 INTUVIE HOLDINGS LLC: COMPANY OVERVIEW 398
TABLE 428 PROMED TECHNOLOGY CO., LIMITED: COMPANY OVERVIEW 399
TABLE 429 MEDCAPTAIN MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 400
TABLE 430 RISK ASSESSMENT: IV EQUIPMENT MARKET 414

LIST OF FIGURES

FIGURE 1 IV EQUIPMENT MARKET: SEGMENTS CONSIDERED & GEOGRAPHICAL SCOPE 35
FIGURE 2 IV EQUIPMENT MARKET: YEARS CONSIDERED 37
FIGURE 3 MARKET SCENARIO 40
FIGURE 4 GLOBAL IV EQUIPMENT MARKET, 2024–2031 41
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IV EQUIPMENT
MARKET, 2022–2025 41
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF IV EQUIPMENT MARKET 42
FIGURE 7 HIGH-GROWTH SEGMENTS IN IV EQUIPMENT MARKET, 2026–2031 43
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN IV EQUIPMENT MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 44
FIGURE 9 GROWING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH 45
FIGURE 10 HOSPITALS SEGMENT IN ASIA PACIFIC REGION ACCOUNTED FOR LARGEST SHARE IN 2025 46
FIGURE 11 CHINA TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD 47
FIGURE 12 IV EQUIPMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 48
FIGURE 13 IV EQUIPMENT MARKET: PORTER’S FIVE FORCES ANALYSIS 58
FIGURE 14 IV EQUIPMENT MARKET: SUPPLY CHAIN ANALYSIS 62
FIGURE 15 IV EQUIPMENT MARKET: VALUE CHAIN ANALYSIS 63
FIGURE 16 IV EQUIPMENT MARKET ECOSYSTEM 64
FIGURE 17 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 71
FIGURE 18 INVESTMENT & FUNDING SCENARIO FOR IV EQUIPMENT MARKET PLAYERS 72
FIGURE 19 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR INFUSION PUMP PATENTS (JANUARY 2014–DECEMBER 2025) 83
FIGURE 20 IV EQUIPMENT MARKET: AI USE CASES 87
FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IV EQUIPMENT 96
FIGURE 22 KEY BUYING CRITERIA FOR IV EQUIPMENT, BY TYPE 97
FIGURE 23 NORTH AMERICA: IV EQUIPMENT MARKET SNAPSHOT 164
FIGURE 24 ASIA PACIFIC: IV EQUIPMENT MARKET SNAPSHOT 211
FIGURE 25 REVENUE ANALYSIS OF KEY PLAYERS IN IV EQUIPMENT MARKET, 2023–2025 321
FIGURE 26 GLOBAL MARKET SHARE ANALYSIS OF KEY PLAYERS IN IV EQUIPMENT
MARKET, 2025 322
FIGURE 27 US MARKET SHARE ANALYSIS OF KEY PLAYERS IN IV EQUIPMENT MARKET, 2025 323
FIGURE 28 EUROPE MARKET SHARE ANALYSIS OF KEY PLAYERS IN IV EQUIPMENT
MARKET, 2025 323
FIGURE 29 IV EQUIPMENT MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 325
FIGURE 30 IV EQUIPMENT MARKET: COMPANY FOOTPRINT 326
FIGURE 31 IV EQUIPMENT MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 329
FIGURE 32 EV/EBITDA OF KEY VENDORS 331
FIGURE 33 YEAR-TO-DATE PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 331
FIGURE 34 IV EQUIPMENT MARKET: BRAND/PRODUCT COMPARISON 332
FIGURE 35 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2025) 337
FIGURE 36 B. BRAUN SE: COMPANY SNAPSHOT (2024) 343
FIGURE 37 BAXTER: COMPANY SNAPSHOT (2024) 350
FIGURE 38 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2024) 355
FIGURE 39 ICU MEDICAL, INC.: COMPANY SNAPSHOT (2024) 360
FIGURE 40 TERUMO CORPORATION: COMPANY SNAPSHOT (2024) 365
FIGURE 41 MOOG INC.: COMPANY SNAPSHOT (2024) 368
FIGURE 42 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2024) 371
FIGURE 43 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2024) 373
FIGURE 44 CARDINAL HEALTH: COMPANY SNAPSHOT (2025) 377
FIGURE 45 AVANOS MEDICAL, INC.: COMPANY SNAPSHOT (2024) 380
FIGURE 46 NIPRO: COMPANY SNAPSHOT (2024) 382
FIGURE 47 JMS CO., LTD.: COMPANY SNAPSHOT (2024) 385
FIGURE 48 IV EQUIPMENT MARKET: RESEARCH DESIGN 401
FIGURE 49 PRIMARY SOURCES 403
FIGURE 50 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (SUPPLY SIDE) 405
FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (DEMAND SIDE) 405
FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 406
FIGURE 53 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 407
FIGURE 54 REVENUE SHARE ANALYSIS ILLUSTRATION: BECTON, DICKINSON AND COMPANY 407
FIGURE 55 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF IV EQUIPMENT MARKET (2025–2030) 409
FIGURE 56 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 410
FIGURE 57 TOP-DOWN APPROACH 410
FIGURE 58 BOTTOM-UP APPROACH 411
FIGURE 59 MARKET DATA TRIANGULATION METHODOLOGY 412

---

---